Genomic Vision: Financial Information for the Third Quarter of 2021
28 Octobre 2021 - 6:00PM
Business Wire
- Revenue from sales down 13% in Q3 2021
- Financial resources providing visibility for the next 12
months
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a
biotechnology company that develops tools and services dedicated to
the analysis and control of changes in the genome, today announced
its 9-month revenue and cash position at September 30, 2021.
Revenue for the third quarter and first 9 months of
2021
9 months
3rd quarter
In thousands of euros – IFRS
2021
2020
∆
2021
2020
∆
Life science research (LSR) market
595
695
-14%
148
145
+2%
In-vitro diagnostics (IVD)
25
100
-75%
5
31
-84%
Total revenue from sales
620
795
-22%
153
176
-13%
Other revenue
320
206
55%
81
75
+8%
Total revenue from activity
940
1,001
-6%
234
251
-7%
Revenue from sales totaled €620 thousand at the end of
September 2021, down 22% compared with the same period in 2020.
This fall was notably the result of the lack of any platform sales
over the period while, in the first quarter of 2020, Genomic Vision
sold a platform to the Leibnitz Institute on Aging - Fritz Lipmann
Institute (FLI) in Germany, within the framework of collaboration
that is actively continuing.
Total revenue from activity, once other revenue is taken
into account, was down 6% as of September 30, 2021, compared with
the same period in 2020. Other revenue, which totaled €320
thousand, mainly corresponded to Research Tax Credit, which is
higher than last year as a result of the R&D focus in 2021.
As previously disclosed, within the context of the public health
crisis that has heavily impacted Genomic Vision’s activities, and
therefore its revenue, the Company has undertaken, during 2021, a
sizeable R&D focus on targeted programs in order to strengthen
its commercial offer. These efforts were materialized notably by
the launch of TeloSizer® service in late September. This innovative
solution expands Genomic Vision’s offering in the field of telomere
biology and cellular health analysis.
The orders booked over the last few months are showing first
signs of an upturn whose effects should be felt from the last
quarter of this year.
Financial structure at September 30, 2021
At September 30, 2021, Genomic Vision had cash and cash
equivalents of €1.4 million, versus €2 million at December 31,
2020. This position takes into account the drawdown of €3 million
during the first half within the framework of the OCABSA program
implemented with Winance in June 2020. The company has still the
opportunity to drawdown the balance of up to €8 million in bond
issue over the next 2.5 years through this program.
Based on revised growth, sales and Research & Development,
Sales & Marketing and General & Administrative spending
assumptions, as well as assumptions regarding its associated
working capital requirements, Genomic Vision will thus have the
necessary financial resources to continue its development over the
next 12 months.
***
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing products
and services dedicated to the analysis (structural and functional)
of genome modifications as well as to the quality and safety
control of these modifications, in particular in genome editing
technologies and biomanufacturing processes. Genomic Vision
proprietary tools, based on DNA combing technology and artificial
intelligence, provide robust quantitative measurements needed to
high confidence characterization of DNA alteration in the genome.
These tools are mainly used for monitoring DNA replication in
cancerous cell, for early cancer detection and the diagnosis of
genetic diseases. Genomic Vision, based near Paris in Bagneux, is a
public listed company listed in compartment C of Euronext’s
regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
***
Member of the CAC® Mid & Small and CAC®
All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the universal
registration document filed with the AMF on February 9, 2021 under
reference number R.21-002, available on the web site of Genomic
Vision (www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211028005844/en/
Genomic Vision Dominique Remy-Renou CEO Tel.: +33 1 49 08
07 51 investisseurs@genomicvision.com
Ulysse Communication Press Relations Bruno Arabian
Tel.: +33 1 42 68 29 70
barabian@ulysse-communication.com
NewCap Investor Relations & Strategic
Communications Tel.: +33 1 44 71 94 94 gv@newcap.eu
Genomic Vision (EU:GV)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Genomic Vision (EU:GV)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024